1. Bluesky Feeds /
  2. Medsky Topics /
  3. GLP-1 Agonists
GLP-1 Agonists

GLP-1 Agonists

by Medsky Topics Medsky Topics

A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.social

Feed on Bluesky

Feeds Stats

  • šŸ’™ Liked by 15 users
  • šŸ“… Updated 7 days ago
  • āš™ļø Provider graze.social
  • šŸ“ˆ In the last 30 days, there was 1 post about this feed. This post got a total of 5 likes and had 0 reposts.

Feed Preview for GLP-1 Agonists

Kansas Reflector
@kansasreflector.com
30 minutes ago
States retreat from covering drugs for weight loss | via @chatlanis.bsky.social #ksleg
States retreat from covering drugs for weight loss ā€¢ Kansas Reflector

kansasreflector.com

States retreat from covering drugs for weight loss ā€¢ Kansas Reflector

Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for the cuts included in President Donald Trumpā€™s broad tax and spending law.
0
4
7
MedPage Today
@medpagetoday.com
about 1 hour ago
The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. Read more at: www.medpagetoday.com/neurā€¦
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug

www.medpagetoday.com

Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug

Oral semaglutide fails to slow clinical progression, but biomarker changes emerge
0
1
4
MedPage Today
@medpagetoday.com
1 day ago
Weight regain after the withdrawal of tirzepatide (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read more at: www.medpagetoday.com/endoā€¦
Cardiometabolic Gains Backslide After Halting Obesity Meds

www.medpagetoday.com

Cardiometabolic Gains Backslide After Halting Obesity Meds

Discontinuing tirzepatide didn't just lead to weight regain
0
0
2
The Atlantic
@theatlantic.com
1 day ago
The next generation of GLP-1 drugs are coming, with more options that promise to be tailored to the health needs of individual patients, Sarah Zhang reports:
The Era of Custom Weight-Loss Drugs Is Coming

bit.ly

The Era of Custom Weight-Loss Drugs Is Coming

The next-generation ā€œGLP-1 plusā€ drugs will be tailored to the health needs of individual patients.
4
6
31
Adriel Bettelheim
@abettel.bsky.social
1 day ago
How GLP-1 drugs are going from niche to mainstream. www.axios.com/2025/11/29/w...
Weight loss drugs go from niche to mainstream

www.axios.com

Weight loss drugs go from niche to mainstream

New pricing deals and aggressive marketing are transforming GLP-1s.
0
0
1
IrishStar.com
@irishstar.com
1 day ago
Former First Lady Michelle Obama is being hit with wild allegations that she is on the Type 2 Diabetes drug Ozempiz after she appeared slimmer in a recent photo shoot.
Michelle Obama hit with wild Ozempic allegations after latest photoshoot

www.irishstar.com

Michelle Obama hit with wild Ozempic allegations after latest photoshoot
7
1
1
JAMA
@jama.com
1 day ago
From 2020 to 2025, prior authorization for #GLP1-RAs became near-universal and out-of-pocket costs rose substantially in 2025, as plans increasingly required coinsurance. ja.ma/48rsOKe
JAMA research letter titled "Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists", includes 4 graphs showing trends from 2020-2025. The graphs depict formulary coverage, prior authorization, monthly out-of-pocket costs, and coinsurance requirements.
0
0
0
The Lancet Diabetes & Endocrinology
@thelancetendo.bsky.social
1 day ago
Although #GLP-1-based therapy might remain a practical term for the near future, given the central role of GLP-1 in most current molecules and coformulations, there is a clear need for broader, more inclusive terminology thelancet.com/journals/lan... #incretins #GLP-1 #GIP #MedSky #EndoSky
Beyond a singular focus on GLP-1: why we need a new nomenclature now

thelancet.com

Beyond a singular focus on GLP-1: why we need a new nomenclature now

The development of glucagon-like peptide-1 (GLP-1)-based therapies for type 2 diabetes and obesity illustrates a remarkable evolution in scientific understanding and therapeutic innovation.1 As the fi...
0
1
3
The Lancet Diabetes & Endocrinology
@thelancetendo.bsky.social
1 day ago
The extent to which newer, #incretin-based drugs for #obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest www.thelancet.com/journalā€¦. #GLP-1 #GIP #MedSky #EndoSky
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions

www.thelancet.com

Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in...
0
1
3
The Lancet Diabetes & Endocrinology
@thelancetendo.bsky.social
1 day ago
Cardiometabolic diseases can have detrimental effects on bone health, leading to fractures, morbidity & mortality, & reduced quality of life. Despite these known relationships, bone health is often underestimated & overlooked in this context www.thelancet.com/journalā€¦. #incretins #GLP-1 #GIP
The gutā€“bone axis: implications of gut hormone-based therapies for bone health

www.thelancet.com

The gutā€“bone axis: implications of gut hormone-based therapies for bone health

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel increases in serious and potentially fatal comorbidities, particularly type 2 dia...
0
0
1
The Lancet Diabetes & Endocrinology
@thelancetendo.bsky.social
1 day ago
#Incretins could serve as a crucial evolutionary link between digestion & substrate oxidation, orchestrating substrate allocation to optimise the body's fight or flight response www.thelancet.com/journalā€¦. #GLP-1 #GIP #digestion #metabolism #cardiovascular system #EndoSky #GastroSky
0
0
2
Euractiv
@euractiv.com
1 day ago
Novo Nordisk warns EU loophole may fuel fake Ozempic trade, pharmacists push back
Novo Nordisk warns EU loophole may fuel fake Ozempic trade, pharmacists push back

dlvr.it

Novo Nordisk warns EU loophole may fuel fake Ozempic trade, pharmacists push back

Drugmakers warn of a 'Wild West' of unauthorised medicines as pharmacists call it a false alarm
0
1
1
Euractiv
@euractiv.com
1 day ago
Novo Nordisk warns EU loophole may fuel fake Ozempic trade, pharmacists push back: Drugmakers warn of a 'Wild West' of unauthorised medicines as pharmacists call it a false alarm
Novo Nordisk warns EU loophole may fuel fake Ozempic trade, pharmacists push back

dlvr.it

Novo Nordisk warns EU loophole may fuel fake Ozempic trade, pharmacists push back

Drugmakers warn of a 'Wild West' of unauthorised medicines as pharmacists call it a false alarm
0
1
0
Endocrine Society Journals
@endosocjournals.bsky.social
2 days ago
GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer. Read more in #JES: bit.ly/4acTEYP #alcoholusedisorder #addiction #GLP-1 @endocrinesociety.bsky.social
GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer

bit.ly

GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer

Abstract. Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychologi
0
2
1
USA TODAY
@usatoday.com
2 days ago
Beyond weight loss, berberine also has a few other potential benefits to be aware of.
Is this trendy supplement really 'natureā€™s Ozempic?' Experts on berberine

bit.ly

Is this trendy supplement really 'natureā€™s Ozempic?' Experts on berberine

Beyond weight loss, berberine also has a few other potential benefits to be aware of.
0
1
6
JAMA Internal Medicine
@jamainternalmed.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/44rKzHU
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
1
JAMA Neurology
@jamaneurology.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4ahLJcG
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Network Open
@jamanetworkopen.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/48iFbrH
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Pediatrics
@jamapediatrics.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/44x4Trp
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Surgery
@jamasurgery.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/49M0UuK
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Otolaryngology
@jamaotolaryngology.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4akt7sB
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Ophthalmology
@jamaophthalmology.bsky.social
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/48oHolo
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Health Forum
@jamahealthforum.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4pfbXl2
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA Psychiatry
@jamapsychiatry.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4pBrEm2
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
0
JAMA
@jama.com
2 days ago
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/3M6YBsb
Webinar launch in collaboration with JAMA: "From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults", 1 December 2025, register now.
0
0
1